Alliancebernstein L.P. Arcellx, Inc. Transaction History
Alliancebernstein L.P.
- $280 Billion
- Q4 2024
A detailed history of Alliancebernstein L.P. transactions in Arcellx, Inc. stock. As of the latest transaction made, Alliancebernstein L.P. holds 51,250 shares of ACLX stock, worth $3.27 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
51,250
Previous 57,431
10.76%
Holding current value
$3.27 Million
Previous $4.8 Million
18.62%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding ACLX
# of Institutions
227Shares Held
45MCall Options Held
450KPut Options Held
647K-
Paradigm Biocapital Advisors LP New York, NY4.37MShares$279 Million12.7% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$239 Million20.37% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$224 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY3.48MShares$222 Million8.84% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.33MShares$212 Million0.0% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $2.79B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...